Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy

被引：48

作者：

Durand, JP

Alexandre, J

Guillevin, L

Goldwasser, F

机构：

[1] Univ Paris 05, Med Oncol Unit, Serv Med Interne, Grp Hosp Cochin,GHU Ouest,AP HP, F-75679 Paris, France

[2] Hop Prive Antony, Clin Amandier, Serv Soins Suite Hemato Cancerol, Antony, France

来源：

ANTI-CANCER DRUGS | 2005年 / 16卷 / 05期

关键词：

chemotherapy; oxaliplatin; neuropathy; neurotoxicity; topiramate; venlafaxine;

D O I：

10.1097/00001813-200506000-00015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Venlafaxine (Effexor; Wyeth Lederle), a serotoninergic-like anti-depressant, and Topiramate (Epitomax; Jansen Cilag), a new anti-epileptic drug, share some evidence of clinical activity in the treatment of neuropathic pain. Several anticancer agents have neurosensory toxicity as limiting toxicity of their repeated administration. One of the most recent and the most widely used is oxaliplatin. No medication is presently known to be active against oxaliplatin permanent neurosensory toxicity. We observed that venlafaxine hydrochloride or low-dose topiramate could be active against the permanent neuropathy-related symptoms of oxaliplatin. Both agents allowed pain relief and a significant autonomy improvement. These preliminary results invite us to evaluate further venlafaxine hydrochloride and topiramate for the treatment of permanent anti-cancer chemotherapy-induced neuropathies. Anti-Cancer Drugs 16:587-591 (c) 2005 Lippincott Williams & Wilkins.

引用

页码：587 / 591

页数：5

共 32 条

[1] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].

Andre, T ;

Boni, C ;

Mounedji-Boudiaf, L ;

Navarro, M ;

Tabernero, J ;

Hickish, T ;

Topham, C ;

Zaninelli, M ;

Clingan, P ;

Bridgewater, J ;

Tabah-Fisch, I ;

de Gramont, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351

[2] Acute myopia and angle-closure glaucoma induced by topiramate [J].

Boentert, M ;

Aretz, H ;

Ludemann, P .

NEUROLOGY, 2003, 61 (09) :1306-1306

[3] Oxaliplatin-related side effects: Characteristics and management [J].

Cassidy, J ;

Misset, JL .

SEMINARS IN ONCOLOGY, 2002, 29 (05) :11-20

[4]

Chandramouli Jane, 2002, J Pain Palliat Care Pharmacother, V16, P19

[5] Toxic neuropathy in patients with pre-existing neuropathy [J].

Chaudhry, V ;

Chaudhry, M ;

Crawford, TO ;

Simmons-O'Brien, E ;

Griffin, JW .

NEUROLOGY, 2003, 60 (02) :337-340

[6] Randomized, concentration-controlled trial of topiramate in refractory focal epilepsy [J].

Christensen, J ;

Andreasen, F ;

Poulsen, JH ;

Dam, M .

NEUROLOGY, 2003, 61 (09) :1210-1218

[7] A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis [J].

Cudkowicz, ME ;

Shefner, JM ;

Schoenfeld, DA ;

Brown, RH ;

Johnson, H ;

Qureshi, M ;

Jacobs, M ;

Rothstein, JD ;

Appel, SH ;

Pascuzzi, RM ;

Heiman-Patterson, TD ;

Donofrio, PD ;

David, WS ;

Russell, JA ;

Tandan, R ;

Pioro, EP ;

Felice, KJ ;

Rosenfeld, J ;

Mandler, RN ;

Sachs, GM ;

Bradley, WG ;

Raynor, EM ;

Baquis, GD ;

Belsh, JM ;

Novella, S ;

Goldstein, J ;

Hulihan, J .

NEUROLOGY, 2003, 61 (04) :456-464

[8] Topiramate in migraine prophylaxis -: Results from a placebo-controlled trial with propranolol as an active control [J].

Diener, HC ;

Tfelt-Hansen, P ;

Dahlöf, C ;

Láinez, MJA ;

Sandrini, G ;

Wang, SJ ;

Neto, W ;

Vijapurkar, U ;

Doyle, A ;

Jacobs, D .

JOURNAL OF NEUROLOGY, 2004, 251 (08) :943-950

[9] Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin ± taxane-pretreated ovarian cancer patients [J].

Dieras, V ;

Bougnoux, P ;

Petit, T ;

Chollet, P ;

Beuzeboc, P ;

Borel, C ;

Husseini, F ;

Goupil, A ;

Kerbrat, P ;

Misset, JL ;

Bensmaïne, MA ;

Tabah-Fisch, I ;

Pouillart, P .

ANNALS OF ONCOLOGY, 2002, 13 (02) :258-266

[10] Protection against oxaliplatin acute neurosensory toxicity by venlafaxine [J].

Durand, JP ;

Brezault, C ;

Goldwasser, F .

ANTI-CANCER DRUGS, 2003, 14 (06) :423-425

← 1 2 3 4 →